Efficacy upon 12-weeks after achievement of maximal dose and tolerability of lacosamide as an adjunctive therapy in epilepsy: Real world clinical experience
| Autor: | Yujie Olivia Wang, C.Y. William Leung, Richard Shek-kwan Chang, Hoi Ki Kate Lui, Yu Hin Ian Leung, Hiu Tung Colin Lui |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Lacosamide law.invention Cohort Studies Young Adult 03 medical and health sciences Epilepsy 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Humans 030212 general & internal medicine Child Adverse effect Aged Retrospective Studies Aged 80 and over Dose-Response Relationship Drug business.industry Retrospective cohort study Middle Aged medicine.disease Treatment Outcome Neurology Tolerability Child Preschool Concomitant Hong Kong Anticonvulsants Drug Therapy Combination Female Neurology (clinical) medicine.symptom business Myoclonus 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of the Neurological Sciences. 409:116601 |
| ISSN: | 0022-510X |
| DOI: | 10.1016/j.jns.2019.116601 |
| Popis: | Lacosamide (LCM) is a new generation antiepileptic drug. It has only been available in Asia in recent years. A retrospective study at two hospitals in Hong Kong was performed to investigate the post-marketing efficacy and tolerability of the drug. A total of 81 subjects were recruited, among which 88% had drug-resistant epilepsy. The most common type of epilepsy was focal with unknown etiology. All patients used LCM as adjunctive therapy. The 50% responder rate was 42% at 12 weeks after achievement of maximal dose of LCM. No specific factor correlated with responsiveness including concomitant enzyme-inducing or sodium channel blocking anticonvulsants. Withdrawal rate within first 12 weeks after drug initiation was 14% while that at any time upon follow-up was 23%. Two cases of uncommon adverse reaction of myoclonus were also reported. The mechanism was postulated to be the sodium channel inhibiting action of LCM. Our study has shown LCM to have comparable efficacy and tolerability in post-marketing experience when compared with the landmark randomized controlled trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect